Hillstream BioPharma (HILS) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free HILS Stock Alerts $0.39 +0.01 (+2.63%) (As of 05/21/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 17, 2024 | morningstar.comHill & Smith PLC HILSOctober 31, 2023 | morningstar.comKiromic BioPharma Inc Ordinary Shares KRBPSeptember 22, 2023 | finance.yahoo.comHillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.September 21, 2023 | finance.yahoo.comDawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceSeptember 11, 2023 | finance.yahoo.comHillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic PruritisSeptember 8, 2023 | finance.yahoo.comHillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13August 30, 2023 | benzinga.comHillstream – Drug Maker Licenses Critical New Technology In Fight Against CancerAugust 25, 2023 | seekingalpha.comNMTRQ 9 Meters Biopharma, Inc.August 9, 2023 | finance.yahoo.comHillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023July 20, 2023 | finance.yahoo.comHillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215July 10, 2023 | finance.yahoo.comHillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and BiologicsJuly 6, 2023 | finance.yahoo.comHillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian CancersJune 9, 2023 | finance.yahoo.comHILS - Hillstream BioPharma, Inc.May 15, 2023 | finance.yahoo.comHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly AndersonMay 4, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma to Present at Upcoming May 2023 Investor and Industry ConferencesApril 29, 2023 | benzinga.comHillstream BioPharma Stock (NASDAQ:HILS), Short Interest ReportApril 28, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Proposed Public OfferingApril 28, 2023 | marketwatch.comHillstream BioPharma Shares Slide Premarket on Stock Offering >HILSApril 28, 2023 | investorplace.comWhy Is Hillstream BioPharma (HILS) Stock Down 57% Today?April 28, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Pricing of Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Announces Pricing of Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Announces Proposed Public OfferingApril 13, 2023 | tmcnet.comHillstream BioPharma Selects OncoBay Clinical to Advance ClinicalApril 13, 2023 | finance.yahoo.comHillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer MechanismApril 12, 2023 | finance.yahoo.comHillstream BioPharma’s Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To GrowApril 11, 2023 | benzinga.comHillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To GrowApril 10, 2023 | finance.yahoo.comHillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical DataMarch 28, 2023 | finance.yahoo.comHillstream BioPharma to Participate in Two Major Industry Conferences in April 2023February 28, 2023 | finance.yahoo.comHillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023February 15, 2023 | finance.yahoo.comHillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price RuleFebruary 13, 2023 | finance.yahoo.comHillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ETFebruary 13, 2023 | finance.yahoo.comHillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian CancerFebruary 10, 2023 | baystreet.caHillstream Nearly Doubles on Test ResultsFebruary 10, 2023 | msn.comHillstream Soars on Promising HSB-1216 Data in Lung CancerFebruary 10, 2023 | finance.yahoo.comIn a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis InducerFebruary 8, 2023 | finance.yahoo.comHillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & LeukemiasFebruary 6, 2023 | finance.yahoo.comHillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant CancersJanuary 31, 2023 | finance.yahoo.comWhy Are Hillstream BioPharma Shares Trading Over 100% Today?January 31, 2023 | finance.yahoo.comHillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant CancersJanuary 31, 2023 | marketbeat.comTrading was temporarily halted for "HILS" at 09:01 AM with a stated reason of "LULD pause."January 17, 2023 | finance.yahoo.comHillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023December 12, 2022 | finance.yahoo.comInsiders who purchased Hillstream BioPharma, Inc. (NASDAQ:HILS) stock last year recover some losses which currently stand at US$86kDecember 9, 2022 | marketbeat.comTrading was temporarily halted for "HILS" at 10:12 AM with a stated reason of "LULD pause."December 1, 2022 | finance.yahoo.comHillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated TargetsOctober 18, 2022 | finance.yahoo.comHillstream’s New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR SymposiumOctober 6, 2022 | finance.yahoo.comHillstream BioPharma, Inc. to Present at Upcoming Investor ConferencesSeptember 21, 2022 | finance.yahoo.comHillstream BioPharma, Inc. (HILS)September 16, 2022 | benzinga.comHillstream BioPharma to Participate in the Fierce... Get Hillstream BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter. Email Address Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. HILS Media Mentions By Week HILS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HILS News Sentiment▼0.000.44▲Average Medical News Sentiment HILS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HILS Articles This Week▼00▲HILS Articles Average Week Get Hillstream BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AIMD News Today ASLN News Today PULM News Today BFRI News Today PCSA News Today XBIO News Today VCNX News Today FWBI News Today TENX News Today ENVB News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HILS) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsWrite this ticker symbol down…StocksToTradeShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceNew Options need New Trading StrategiesNetpicks Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
